Literature DB >> 19029998

Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?

Andrew S Bomback1, Abhijit V Kshirsagar, Philip J Klemmer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19029998      PMCID： PMC2845907          DOI： 10.1038/ncpneph1004

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN： 1745-8323


× No keyword cloud information.
  11 in total

Review 1.  Aldosterone in chronic kidney and cardiac disease.

Authors:  Thomas H Hostetter; Hassan N Ibrahim
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

Review 2.  Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status.

Authors:  Atsuhisa Sato; Takao Saruta
Journal:  Hypertens Res       Date:  2004-05       Impact factor: 3.872

Review 3.  The incidence and implications of aldosterone breakthrough.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Nat Clin Pract Nephrol       Date:  2007-09

4.  Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity.

Authors:  Jazmin M Pérez-Rojas; Stephanie Derive; Jorge A Blanco; Cristino Cruz; Lilia Martínez de la Maza; Gerardo Gamba; Norma A Bobadilla
Journal:  Am J Physiol Renal Physiol       Date:  2005-07-05

5.  Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.

Authors:  Jazmin Pérez-Rojas; Jorge A Blanco; Cristino Cruz; Joyce Trujillo; Vishal S Vaidya; Norma Uribe; Joseph V Bonventre; Gerardo Gamba; Norma A Bobadilla
Journal:  Am J Physiol Renal Physiol       Date:  2006-07-11

6.  Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone.

Authors:  Juan M Mejía-Vilet; Victoria Ramírez; Cristino Cruz; Norma Uribe; Gerardo Gamba; Norma A Bobadilla
Journal:  Am J Physiol Renal Physiol       Date:  2007-03-20

7.  Plasma aldosterone is independently associated with the metabolic syndrome.

Authors:  Murielle Bochud; Jürg Nussberger; Pascal Bovet; Marc R Maillard; Robert C Elston; Fred Paccaud; Conrad Shamlaye; Michel Burnier
Journal:  Hypertension       Date:  2006-06-19       Impact factor: 10.190

Review 8.  Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.

Authors:  Andrew S Bomback; Abhijit V Kshirsagar; M Ahinee Amamoo; Philip J Klemmer
Journal:  Am J Kidney Dis       Date:  2008-02       Impact factor: 8.860

9.  Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration.

Authors:  Rogerio B de Paula; Alexandre A da Silva; John E Hall
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

10.  The role of aldosterone blockade in murine lupus nephritis.

Authors:  Seetha U Monrad; Paul D Killen; Marc R Anderson; Amanda Bradke; Mariana J Kaplan
Journal:  Arthritis Res Ther       Date:  2008-01-15       Impact factor: 5.156
View more
  4 in total

1.  The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.

Authors:  Nicola C Edwards; Richard P Steeds; Colin D Chue; Paul M Stewart; Charles J Ferro; Jonathan N Townend
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

Review 2.  Aldosterone: effects on the kidney and cardiovascular system.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

3.  Mineralocorticoid receptor blockade-a novel approach to fight hyperkalaemia in chronic kidney disease.

Authors:  E Ritz; B Pitt
Journal:  Clin Kidney J       Date:  2013-09-01

Review 4.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.

Authors:  Peter Kolkhof; Lars Bärfacker
Journal:  J Endocrinol       Date:  2017-07       Impact factor: 4.286
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.